Open-house discount agreements for Naproxen
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naproxen, ATC M01AE02
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...
Only pharmaceutical companies are eligible as potential contract partners.
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive open-house discount agreements for pharmaceutical products concerning Naproxen, ATC M01AE02.
- Supply contract model for a medicinal product discount agreement under § 130a(8) SGB V, as described in the notice.
Show full summary
Open-house supply arrangement for Naproxen (ATC M01AE02) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-exclusive, non-negotiated accession model, not a classic competitive award procedure. No contract value is stated. Submission is possible electronically with a qualified electronic signature or in paper form, with strict monthly cut-off rules and a final deadline of 05.09.2026.
Risks
For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...
Only pharmaceutical companies are eligible as potential contract partners.
Submission deadline in 8 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- The signatory's authority must be evidenced by the commercial register extract; otherwise a power of attorney must be provided.
Administrative
- Submit a signed contract, the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and the signed declaration of reliability.
- Submissions must be either handwritten on paper or electronically with a qualified electronic signature.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open-house discount agreements for Naproxen
Single lot covering non-exclusive open-house pharmaceutical discount agreements for the active substance Naproxen (ATC M01AE02). The lot is for supplies and performance is in Germany, Bavaria (DE212). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical terms. Lot information comes from structured data and notice text.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Naproxen, ATC M01AE02
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Sep 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 558157-2024
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...
Only pharmaceutical companies are eligible as potential contract partners.
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications